Roche Take-Over of InterMune A "Rebuke" To FDA

The Wall Street Journal editorial board has an interesting take on Roche’s takeover of InterMune, calling it a “rebuke” of the FDA, and a "guided missile" aimed at the bureaucracy.

I’m not quite sure how the takeover is a “guided missile” at the FDA: Corporate takeovers do not change the behavior of the FDA. Nevertheless, the editorial introduces an interesting way to look at the harm the FDA does.

Read the entire column at NCPA's Health Policy Blog.